Ftse Mib
38.429,34
-0,11%
DAX
22.421,36
0,00%
S&P 500
5.983,25
-0,50%
NASDAQ
19.286,92
-1,21%
Bitcoin
89.935,80
-1,68%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Capricor Therapeutics Inc (CAPR) Capricor Therapeutics Inc (CAPR) Notizie

CAPR

Capricor Therapeutics (CAPR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CAPR
DataOraFonteTitoloSimboloCompagnia
10/02/202515:00GlobeNewswire Inc.Capricor Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
05/02/202523:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CAPRCapricor Therapeutics Inc
07/01/202501:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
02/01/202520:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
02/01/202515:15GlobeNewswire Inc.Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
02/12/202422:15GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
20/11/202415:00GlobeNewswire Inc.Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines AgencyNASDAQ:CAPRCapricor Therapeutics Inc
14/11/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
13/11/202422:01GlobeNewswire Inc.Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
12/11/202417:46Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CAPRCapricor Therapeutics Inc
12/11/202415:00GlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
12/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CAPRCapricor Therapeutics Inc
05/11/202415:00GlobeNewswire Inc.Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13NASDAQ:CAPRCapricor Therapeutics Inc
22/10/202423:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
18/10/202422:01GlobeNewswire Inc.Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:CAPRCapricor Therapeutics Inc
17/10/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CAPRCapricor Therapeutics Inc
17/10/202412:00GlobeNewswire Inc.Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common StockNASDAQ:CAPRCapricor Therapeutics Inc
16/10/202422:17GlobeNewswire Inc.Capricor Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:CAPRCapricor Therapeutics Inc
16/10/202419:31Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
11/10/202415:15GlobeNewswire Inc.Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society CongressNASDAQ:CAPRCapricor Therapeutics Inc
09/10/202415:15GlobeNewswire Inc.Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
04/10/202415:15GlobeNewswire Inc.Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society CongressNASDAQ:CAPRCapricor Therapeutics Inc
24/09/202422:03Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
24/09/202414:00GlobeNewswire Inc.Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyNASDAQ:CAPRCapricor Therapeutics Inc
23/09/202415:25GlobeNewswire Inc.Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024NASDAQ:CAPRCapricor Therapeutics Inc
17/09/202415:15GlobeNewswire Inc.Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
06/09/202414:30GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
23/08/202422:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
07/08/202422:05GlobeNewswire Inc.Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
31/07/202415:00GlobeNewswire Inc.Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7NASDAQ:CAPRCapricor Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CAPR

La tua Cronologia

BIT
LDO
Leonardo
BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
MONC
Moncler
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
NEXI
Nexi S.p.A
BIT
TEN
Tenaris
BIT
FCT
Fincantieri
BIT
CPR
Davide Campari
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci